New Strategies for RET Inhibition May Expand Their Role in NSCLC
RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.
RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.
HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo…
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS…
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.